Retrospective Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Jul 16, 2024; 12(20): 4074-4081
Published online Jul 16, 2024. doi: 10.12998/wjcc.v12.i20.4074
Figure 1
Figure 1 Quality of life of patients in the control and research groups. A-F: Quality of life of patients measured using the physical function (A), role function (B), emotional function (C), social function (D), cognitive function (E), and overall health scores (F). aP < 0.05 vs before treatment. bP < 0.01 vs before treatment.
Figure 2
Figure 2 Survival as measured using the 1-year overall survival and 1-year recurrence and metastasis rates. A: 1-year overall survival; B: 1-year recurrence and metastasis rates.
Figure 3
Figure 3 Comparison of levels of serum inflammatory factors after treatment between the control and research groups. A: Interleukin (IL)-6; B: IL-10; C: Tumor necrosis factor alpha. aP < 0.05 vs before treatment. bP < 0.01 vs before treatment; cP < 0.05 vs control group. IL: Interleukin; TNF-α: Tumor necrosis factor alpha.